Every material Form 8-K Armata Pharmaceuticals, Inc. has filed with the SEC since August 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Armata Pharmaceuticals said it received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support the Phase 3 program for AP-SA02, its lead clinical candidate. The company said this is the first DoW funding specifically for Phase 3 execution, and it lifts cumulative non-dilutive DoW support for the program to approximately $32.4 million, which may reduce the need to raise capital through share sales.
Armata received $3.7 million in additional non-dilutive funds from the U.S. Department of War, announced September 23, 2026.
The award is administered through the Medical Technology Enterprise Consortium and funded by the Defense Health Agency and Joint Warfighter Medical Research Program.
Cumulative non-dilutive DoW funding under the award is approximately $32.4 million, following $28.7 million previously provided.
The company plans to start a Phase 3 superiority study of AP-SA02 in complicated S. aureus bacteremia in the second half of 2026.
The FDA granted Breakthrough Therapy designation to Armata's AP-SA02, an intravenous multi-phage product candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia. The company says the designation is intended to expedite review and that AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, but the filing discloses no revenue, earnings or financing figures.
FDA granted Breakthrough Therapy designation to AP-SA02 for complicated bacteremia caused by MSSA or MRSA, announced September 14, 2026.
AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations.
In the Phase 1b/2a diSArm study, 100% of AP-SA02 patients maintained clinical response without relapse at 28 days after completion of BAT, compared with 75% on placebo plus BAT.
The company plans a Phase 3 superiority study, anticipated to start in the second half of 2026.
Armata Pharmaceuticals reported second-quarter 2026 net income of $74.1 million, driven by a $91.0 million non-cash gain from the change in fair value of its Convertible Loan. Operating loss widened to $10.3 million from $6.8 million a year earlier, and the company's cash and equivalents were $24.0 million at June 30, 2026, so the profit does not reflect improved operations.
Q2 2026 grant and award revenue was $2.5 million, up from $2.2 million in Q2 2025.
Q2 2026 research and development expenses rose to $7.6 million and general and administrative expenses to $5.2 million, mainly from higher non-cash stock-based compensation.
Q2 2026 diluted loss per share was $0.27, compared with $0.45 in Q2 2025; basic earnings per share were $2.02.
Six-month net loss widened to $41.2 million from $22.8 million; cash and equivalents were $24.0 million at June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Armata Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →